OncoMatch/Endometrial / Uterine Cancer/PD-L1 (CD274)
Endometrial / Uterine CancerPD-L1 (CD274) Clinical Trials
PD-L1 expression is primarily a stratification factor in endometrial cancer trials rather than a key eligibility biomarker. The main IO approvals in endometrial cancer are driven by MMR/MSI-H status (see MMR page); pembrolizumab plus lenvatinib is approved regardless of PD-L1 level. Trials that include PD-L1 CPS as an eligibility criterion in endometrial cancer are uncommon; most IO trials use PD-L1 for stratification or exploratory analysis rather than enrollment gating.
Top recruiting PD-L1 (CD274) Endometrial / Uterine Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Browse other molecular targets with active Endometrial / Uterine Cancer trials.